Trial Profile
Phase 1b Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Vaccine Regimen ALVAC-HIV (vCP1521) Followed by AIDSVAX® B/E in Healthy, HIV-1 Uninfected Adult Participants in South Africa
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV gp120 vaccine (Primary) ; HIV vaccine vCP1521 (Primary) ; Hepatitis B vaccine; Tetanus vaccine
- Indications Hepatitis B; HIV-1 infections; Tetanus
- Focus Adverse reactions; Therapeutic Use
- 19 Jun 2019 Status changed from active, no longer recruiting to completed.
- 22 Apr 2014 New trial record